Skip to main content

Vistagen Therapeutics, Inc.

VTGN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001411685

No open-market purchases or sales by Vistagen Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $2.54M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Vistagen Therapeutics, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of VTGN: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders5158+7
Shares15.5M23.4M+7.87M (+50.8%)
Value$30.3M$81.8M+$51.5M (+170.2%)

New holders (14)

Institutions that held Vistagen Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to VTGN in Q3 2025
InstitutionSharesValue% of portfolio
Janus Henderson Group PLC4,165,767$14.7M0.01%
OrbiMed Advisors LLC3,060,000$10.9M0.26%
Soleus Capital Management, L.P.550,000$1.95M0.10%
Citadel Advisors LLC122,062$433.3K0.00%
XTX Topco Ltd69,712$247.5K0.01%
Walleye Capital LLC67,770$240.6K0.00%
Goldman Sachs Group Inc60,152$213.5K0.00%
Cubist Systematic Strategies, LLC43,953$156.0K0.00%
Occudo Quantitative Strategies LP42,704$151.6K0.02%
Gsa Capital Partners LLP31,486$112.0K0.01%
Millennium Management LLC20,676$73.4K0.00%
Quadrature Capital Ltd15,752$55.8K0.00%
Schonfeld Strategic Advisors LLC10,883$38.6K0.00%
FNY Investment Advisers, LLC6,000$21.0K0.01%

Sold out (7)

Institutions that held Vistagen Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of VTGN in Q3 2025
InstitutionShares, Q2 2025Value, Q2 2025
Sphera Funds Management Ltd.447,939$895.9K
Marshall Wace, LLP34,638$69.3K
Virtu Financial LLC22,946$46.0K
Simplex Trading, LLC22,536$45.0K
Tower Research Capital LLC (TRC)7,721$15.4K
Raymond James Financial Inc6,410$12.8K
Royal Bank of Canada3,297$7.00K